Increasing evidence suggests that identification of such combinatorial strategies aiming at synthetic lethality with oncogenic KRAS inhibition might be highly tissue-specific and vary with individual sites of tumor origin and with individual patterns of accompanying oncogenic genomic variants [57]. The gene discussed is KRAS; the disease is neoplasm.